Clinical Trials Logo

Leukemia clinical trials

View clinical trials related to Leukemia.

Filter by:

NCT ID: NCT03564470 Recruiting - Leukemia Clinical Trials

Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL

Start date: February 14, 2016
Phase: Phase 2/Phase 3
Study type: Interventional

Ph-like ALL is a recently recognized high-risk subgroup and the optimal therapeutic approaches are poorly characterized. Based on the pediatric-inspired, PEG-L-asparaginase-intensified and MRD-directed PDT-ALL-2016 protocol, this open-label, two-arm, multi-site trial PDT-Ph-like-ALL is aimed to evaluate the safety and effect of oral histone deacetylase inhibitor chidamide and dasatinib for adult Ph-like ALL.

NCT ID: NCT03558607 Recruiting - Clinical trials for Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Disorder

The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm

Start date: May 17, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This trial aimed to investigate the therapeutic efficacy of ruxolitinib in combination with cytotoxic chemotherapy for post-myeloproliferative neoplasm secondary acute myeloid leukemia.

NCT ID: NCT03556982 Recruiting - Clinical trials for Leukemia, Myeloid, Acute

CART-123 FOR Relapsed/Refractory Acute Myelocytic Leukemia(AML)

Start date: March 1, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficiency of CD123-Targeted CAR-T in Treating Patients with relapsed/refractory AML

NCT ID: NCT03556748 Recruiting - Cancer Clinical Trials

WB-EMS and Nutrition in Patients With Hematological Malignancies

Start date: November 1, 2017
Phase: N/A
Study type: Interventional

This study evaluates the effects of a whole-body electromyostimulation (WB-EMS) training combined with individualized nutritional support on skeletal muscle mass, body composition, muscle strength/function, quality of life, fatigue, pain and gastrointestinal symptoms in patients with hematological malignancies 4-6 weeks before and 4-6 weeks after undergoing stem cell Transplantation. Within this context, this study also investigates the effect of the nutrition and exercise intervention on the period of hospitalization, period of White blood cell recovery and frequency and severity of complications (mucositis, Graft-versus-Host-Disease, infections) after stem cell Transplantation as consequences of the therapeutic immune Suppression.

NCT ID: NCT03555851 Recruiting - Leukemia, Other Clinical Trials

Factors Affecting Post-transplant Cyclophosphamide (PTCy) Efficacy

Start date: July 13, 2018
Phase:
Study type: Observational

This study will examine the influence of donor and recipient pharmacogenetics (PG), drug pharmacokinetics (PK), and T cell phenotypes and how it may permit a tailored dosing strategy to improve the therapeutic index of post-transplant cyclophosphamide (PTCy) and optimize the graft versus tumor effect, while minimizing acute and chronic graft versus host disease (GVHD).

NCT ID: NCT03553238 Recruiting - Leukemia, Acute Clinical Trials

Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL

Start date: February 14, 2016
Phase: Phase 2/Phase 3
Study type: Interventional

ETP-ALL is a recently recognized high-risk subgroup and the optimal therapeutic approaches are poorly characterized. Based on the pediatric-inspired, PEG-L-asparaginase-intensified and MRD-directed PDT-ALL-2016 protocol, this open-label, one-arm, multi-site trial is aimed to evaluate the safety and effect of a novel oral histone deacetylase inhibitor chidamide for adult ETP-ALL/LBL in CHINA.

NCT ID: NCT03547115 Recruiting - Clinical trials for Acute Myeloid Leukemia (AML)

A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML

Start date: May 31, 2018
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label, dose escalation study to determine the safety and preliminary efficacy of voruciclib monotherapy in subjects with relapsed/refractory B cell malignancies or AML after failure of standard therapies or voruciclib in combination with venetoclax in subjects with relapsed or refractory AML

NCT ID: NCT03544021 Recruiting - Clinical trials for Leukemia, Lymphocytic, Acute

CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

Start date: March 1, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficiency of CD19-Targeted CAR-T in Treating Patients with relapsed/refractory acute leukemia.

NCT ID: NCT03534323 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS

Start date: July 12, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This research study is assessing a new drug, duvelisib, in combination with a drug that is already FDA approved, venetoclax, as a possible treatment for participants with CLL or those with Richter's Syndrome

NCT ID: NCT03533816 Recruiting - Clinical trials for Acute Myeloid Leukemia

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

Start date: January 31, 2020
Phase: Phase 1
Study type: Interventional

Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimize graft versus host disease (GVHD) in leukemic and myelodysplastic patients who have had a partially mismatched bone marrow transplant (haploidentical).